About this trial
The purpose of this clinical trial is to learn the safety and efficacy of HDAC inhibitors in combination with neoadjuvant immunochemotherapy compared to neoadjuvant therapy in the treatment of locally advanced colon cancer.
The main questions it aims to answer are:
Can HDAC inhibitors combined with neoadjuvant immunochemotherapy improve the rate of pCR and complete resection in patients? Are HDAC inhibitors combined with neoadjuvant immunochemotherapy safe and reliable? Does the combination of HDAC inhibitors and neoadjuvant immunochemotherapy achieve a better long-term prognosis than neoadjuvant therapy?
Eligibility criteria
Qualifiers
Signed written informed consent to voluntarily join this study
Patients with colon cancer who are assessed by abdominal contrast-enhanced CT/abdominopelvic MRI as high-risk T3 (tumor destroys muscle wall and extends to pericolonic fat, protruding more than 5 mm into adjacent mesenteric fat) or T4 (tumor penetrates the visceral peritoneal surface or directly invades or adheres to adjacent organs or structures).
Adenocarcinoma of the colon confirmed by histopathological examination.
At least 18 years old, male or female.
Disqualifiers
History of previous allergy to monoclonal antibodies, any component of HDACi, and capecitabine;
Received any treatment against the mechanism of action of tumor immunity, such as immunization, HDACi, etc.
Immunosuppressive drugs, or systemic hormonal drugs within 2 weeks prior to the first use of the study drug to achieve immunosuppressive purposes
Receipt of a live attenuated vaccine within 4 weeks prior to the first use of study drug;
Trial design
Treatments tested in this trial
- Chidamide + Tislelizumab + chemotherapy (CapeOX )
- CapeOX
Treatment groups
Sponsors and collaborators
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Lead sponsor
Southwest Hospital, China
Collaborator
Xinqiao Hospital of Chongqing
Collaborator
First Affiliated Hospital of Chongqing Medical University
Collaborator
The Second Affiliated Hospital of Chongqing Medical University
Collaborator
Chongqing Medical University
Collaborator
Chongqing University Cancer Hospital
Collaborator
Chongqing General Hospital
Collaborator
Chongqing Traditional Chinese Medicine Hospital
Collaborator
Chongqing Shapingba District People's Hospital
Collaborator
Chongqing Seventh People's Hospital
Collaborator
Chongqing Renji Hospital, University of Chinese Academy of Sciences
Collaborator
The 13th People's Hospital of Chongqing
Collaborator